BioSpace News Archive

Encompass Health Corp. (NYSE: EHC) today announced it will participate in the Credit Suisse 30th Annual Virtual Healthcare Conference on November 8, 2021.

The U.S. Food and Drug Administration approved the first interchangeable biosimilar product to treat certain inflammatory diseases.

Alphageneron Pharmaceuticals, Inc. announces the successful completion of a pre-IND (“Investigational New Drug”) meeting with the U.S. Food and Drug Administration (“FDA”)

Prime Therapeutics today introduced IntegratedRx™ - Oncology. This new clinically integrated program streamlines the treatment pathway for members who are fighting cancer so they can now receive their oral oncolytic and companion medications in the clinical setting directly from their oncologist’s clinic or affiliated hospital pharmacy.

Kubota Vision Inc., a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd., announced that the company received Quality Management System - ISO 13485:2016 certification for the design and development of ophthalmic medical devices.

Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announces that it has received Tranche 5 under its financing agreement with the European Investment Bank that was signed in October 2018 and comprises up to EUR 40 million, subject to achieving a set of agreed performance criteria.

Abivax SA today reports new results from an extended set of patients in its ongoing open-label maintenance study, following the phase 2b induction study of once-daily oral 50mg ABX464 to treat ulcerative colitis (UC).

Encodia , a privately held biotech company developing next-generation solutions for proteomics research, announced the hiring of Nigel Beard, Ph.D., as Chief Technology Officer (CTO).

Among the many health challenges facing children is the very real threat of contracting Lyme disease as nearly 30% of the estimated 476,000 people in the U.S. each year who are diagnosed and treated for this disease are ages 0-19. In response to this troubling fact, an important webinar focused on how Lyme disease affects the pediatric population will be held on Thursday, Oct. 21.

JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced the first commercial implants with the Trilogy Heart Valve System in Europe.